Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 138

1.

Obesity and Breast Cancer Outcomes: How Much Evidence Is Needed to Change Practice?

Goodwin PJ.

J Clin Oncol. 2015 Dec 28. pii: JCO647503. [Epub ahead of print] No abstract available.

PMID:
26712225
2.

Progesterone and Synthetic Progestin Controversies--Reply.

Joshi PA, Goodwin PJ, Khokha R.

JAMA Oncol. 2015 Oct;1(7):987-8. doi: 10.1001/jamaoncol.2015.2294. No abstract available.

PMID:
26448288
3.

Recommendations for Obesity Clinical Trials in Cancer Survivors: American Society of Clinical Oncology Statement.

Ligibel JA, Alfano CM, Hershman D, Ballard RM, Bruinooge SS, Courneya KS, Daniels EC, Demark-Wahnefried W, Frank ES, Goodwin PJ, Irwin ML, Levit LA, McCaskill-Stevens W, Minasian LM, O'Rourke MA, Pierce JP, Stein KD, Thomson CA, Hudis CA.

J Clin Oncol. 2015 Nov 20;33(33):3961-7. doi: 10.1200/JCO.2015.63.1440. Epub 2015 Aug 31. No abstract available.

PMID:
26324364
4.

Obesity, insulin resistance and breast cancer outcomes.

Goodwin PJ.

Breast. 2015 Nov;24 Suppl 2:S56-9. doi: 10.1016/j.breast.2015.07.014. Epub 2015 Aug 15.

PMID:
26283600
5.

Progesterone Exposure and Breast Cancer Risk: Understanding the Biological Roots.

Joshi PA, Goodwin PJ, Khokha R.

JAMA Oncol. 2015 Jun;1(3):283-5. doi: 10.1001/jamaoncol.2015.0512. No abstract available.

PMID:
26181171
6.

Modifiable Lifestyle Factors and Breast Cancer Outcomes: Current Controversies and Research Recommendations.

Goodwin PJ, Ambrosone CB, Hong CC.

Adv Exp Med Biol. 2015;862:177-92. doi: 10.1007/978-3-319-16366-6_12. Review.

PMID:
26059936
7.

Comorbidities and Their Management: Potential Impact on Breast Cancer Outcomes.

Hong CC, Ambrosone CB, Goodwin PJ.

Adv Exp Med Biol. 2015;862:155-75. doi: 10.1007/978-3-319-16366-6_11. Review.

PMID:
26059935
8.

Host Factors and Risk of Breast Cancer Recurrence: Genetic, Epigenetic and Biologic Factors and Breast Cancer Outcomes.

Ambrosone CB, Hong CC, Goodwin PJ.

Adv Exp Med Biol. 2015;862:143-53. doi: 10.1007/978-3-319-16366-6_10. Review.

PMID:
26059934
9.

Breast Cancer Survivorship: Where Are We Today?

Ganz PA, Goodwin PJ.

Adv Exp Med Biol. 2015;862:1-8. doi: 10.1007/978-3-319-16366-6_1.

PMID:
26059925
10.

Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study.

Dowling RJ, Niraula S, Chang MC, Done SJ, Ennis M, McCready DR, Leong WL, Escallon JM, Reedijk M, Goodwin PJ, Stambolic V.

Breast Cancer Res. 2015 Mar 3;17:32. doi: 10.1186/s13058-015-0540-0.

11.

Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer.

Lohmann AE, Chapman JA, Burnell MJ, Levine MN, Tsvetkova E, Pritchard KI, Gelmon KA, O'Brien P, Han L, Rugo HS, Albain KS, Perez EA, Vandenberg TA, Chalchal HI, Sawhney RP, Shepherd LE, Goodwin PJ.

Breast Cancer Res Treat. 2015 Apr;150(3):605-11. doi: 10.1007/s10549-015-3355-x. Epub 2015 Apr 2.

PMID:
25833209
12.

Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32.

Goodwin PJ, Parulekar WR, Gelmon KA, Shepherd LE, Ligibel JA, Hershman DL, Rastogi P, Mayer IA, Hobday TJ, Lemieux J, Thompson AM, Pritchard KI, Whelan TJ, Mukherjee SD, Chalchal HI, Oja CD, Tonkin KS, Bernstein V, Chen BE, Stambolic V.

J Natl Cancer Inst. 2015 Mar 4;107(3). pii: djv006. doi: 10.1093/jnci/djv006. Print 2015 Mar.

PMID:
25740979
13.

Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial.

Hadad SM, Coates P, Jordan LB, Dowling RJ, Chang MC, Done SJ, Purdie CA, Goodwin PJ, Stambolic V, Moulder-Thompson S, Thompson AM.

Breast Cancer Res Treat. 2015 Feb;150(1):149-55. doi: 10.1007/s10549-015-3307-5. Epub 2015 Feb 15.

PMID:
25682077
14.

Impact of the obesity epidemic on cancer.

Goodwin PJ, Stambolic V.

Annu Rev Med. 2015;66:281-96. doi: 10.1146/annurev-med-051613-012328. Epub 2014 Nov 12. Review.

PMID:
25423596
15.

Twenty-twenty hindsight: an adjuvant breast cancer trial through the retrospectoscope.

Goodwin PJ, Ballman KV, Levine M.

J Clin Oncol. 2014 Aug 1;32(22):2284-6. doi: 10.1200/JCO.2014.55.9344. Epub 2014 Jun 16. No abstract available.

16.

Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial.

Goodwin PJ, Segal RJ, Vallis M, Ligibel JA, Pond GR, Robidoux A, Blackburn GL, Findlay B, Gralow JR, Mukherjee S, Levine M, Pritchard KI.

J Clin Oncol. 2014 Jul 20;32(21):2231-9. doi: 10.1200/JCO.2013.53.1517. Epub 2014 Jun 16.

17.

Past, present, and future challenges in breast cancer treatment.

Sledge GW, Mamounas EP, Hortobagyi GN, Burstein HJ, Goodwin PJ, Wolff AC.

J Clin Oncol. 2014 Jul 1;32(19):1979-86. doi: 10.1200/JCO.2014.55.4139. Epub 2014 Jun 2. No abstract available.

18.

Hype versus hope: metformin and vitamin D as anticancer agents.

Lohmann AE, Goodwin PJ.

Am Soc Clin Oncol Educ Book. 2014:e69-74. doi: 10.14694/EdBook_AM.2014.34.e69. Review.

19.

Pain in patients with cancer.

Goodwin PJ, Bruera E, Stockler M.

J Clin Oncol. 2014 Jun 1;32(16):1637-9. doi: 10.1200/JCO.2014.55.3818. Epub 2014 May 5. No abstract available.

20.

Blood levels of vitamin D and early stage breast cancer prognosis: a systematic review and meta-analysis.

Rose AA, Elser C, Ennis M, Goodwin PJ.

Breast Cancer Res Treat. 2013 Oct;141(3):331-9. doi: 10.1007/s10549-013-2713-9. Epub 2013 Oct 9. Review.

PMID:
24104883
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk